文献速递消化系统肿瘤

小肠腺癌的基因组分析

Genomic Profiling of Small-Bowel Adenocarcinoma.
PubMed 文献 · JAMA Oncol · 2017-01-01

这项前瞻性分析对317例小肠腺癌、6353例结直肠癌和889例胃癌的临床样本进行了基于杂交捕获的基因组分析,发现小肠腺癌的基因组改变与结直肠癌和胃癌存在显著差异,91%的小肠腺癌病例中可识别出潜在可靶向的基因组改变,且微卫星不稳定性和肿瘤突变负荷较高,提示免疫治疗可能发挥作用。

要点

  • 小肠腺癌的APC突变频率为26.8%,低于结直肠癌的75.9%和胃癌的7.8%。
  • 小肠腺癌的KRAS突变频率为53.6%,高于胃癌的14.2%。
  • 91%的小肠腺癌病例可识别出潜在可靶向的基因组改变。

核心结论

  • 小肠腺癌在基因组层面与结直肠癌和胃癌存在显著差异,是一种分子上独特的肠道肿瘤。
  • 基因组分析可在91%的小肠腺癌病例中识别出潜在可靶向的基因组改变。
  • 小肠腺癌中微卫星不稳定性和肿瘤突变负荷的发生率较高,提示免疫治疗可能发挥作用。

研究设计与样本

  • 前瞻性分析于2012年8月24日至2016年2月3日期间收集临床样本,包括小肠腺癌317例、结直肠癌6353例和胃癌889例。
  • 采用基于杂交捕获的基因组分析,由个体主治医师在临床诊疗过程中为制定治疗决策而申请。
  • 共分析7559例患者,其中男性4138例(54.7%),中位年龄56岁(范围12-101岁)。

主要发现

  • 小肠腺癌中APC改变频率为26.8%(85/317),低于结直肠癌的75.9%(4823/6353),P < .001;CDKN2A改变频率为14.5%(46/317),高于结直肠癌的2.6%(165/6353),P < .001。
  • 小肠腺癌中KRAS改变频率为53.6%(170/317),高于胃癌的14.2%(126/889),P < .001;APC改变频率为26.8%(85/317),高于胃癌的7.8%(69/889),P < .001;SMAD4改变频率为17.4%(55/317),高于胃癌的5.2%(46/889),P < .001。
  • BRAF突变在结直肠癌中占7.6%(484/6353),在小肠腺癌中占9.1%(29/317),但V600E突变在小肠腺癌中较少见,仅占BRAF突变病例的10.3%(3/29)。
  • 小肠腺癌中ERBB2/HER2点突变频率为8.2%(26/317),微卫星不稳定性为7.6%(13/170),高肿瘤突变负荷为9.5%(30/317)。
  • 未特定类型小肠腺癌与十二指肠腺癌的分子谱存在显著差异,炎症性肠病相关小肠腺癌的分子谱也有显著差异。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出,基因组分析可在多数小肠腺癌病例(91%)中识别出潜在可靶向的基因组改变。
  • 作者指出,小肠腺癌中微卫星不稳定性和肿瘤突变负荷发生率较高,提示免疫治疗可能发挥作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Small-bowel adenocarcinomas (SBAs) are rare cancers with a significantly lower incidence, later stage at diagnosis, and worse overall survival than other intestinal-derived cancers. To date, comprehensive genomic analysis of SBA is lacking. OBJECTIVE: To perform in-depth genomic characterization of a large series of SBAs and other gastrointestinal tumors to draw comparisons and identify potentially clinically actionable alterations. DESIGN, SETTING, AND PARTICIPANTS: Prospective analysis was performed of clinical samples from patients with SBA (n = 317), colorectal cancer (n = 6353), and gastric carcinoma (n = 889) collected between August 24, 2012, and February 3, 2016, using hybrid-capture-based genomic profiling, at the request of the individual treating physicians in the course of clinical care for the purpose of making therapy decisions. RESULTS: Of the 7559 patients included in analysis, 4138 (54.7%) were male; the median age was 56 (range, 12-101) years. The frequency of genomic alterations seen in SBA demonstrated distinct differences in comparison with either colorectal cancer (APC: 26.8% [85 of 317] vs 75.9% [4823 of 6353], P < .001; and CDKN2A: 14.5% [46 of 317] vs 2.6% [165 of 6353], P < .001) or gastric carcinoma (KRAS: 53.6% [170 of 317] vs 14.2% [126 of 889], P < .001; APC: 26.8% [85 of 317] vs 7.8% [69 of 889], P < .001; and SMAD4: 17.4% [55 of 317] vs 5.2% [46 of 889], P < .001). BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases. The ERBB2/HER2 point mutations (8.2% [26 of 317]), microsatellite instability (7.6% [13 of 170]), and high tumor mutational burden (9.5% [30 of 317]) were all enriched in SBA. Significant differences were noted in the molecular profile of unspecified SBA compared with duodenal adenocarcinoma, as well as in inflammatory bowel disease-associated SBAs. Targetable alterations in several additional genes, including PIK3CA and MEK1, and receptor tyrosine kinase fusions, were also identified in all 3 series. CONCLUSIONS AND RELEVANCE: This study presents to our knowledge the first large-scale genomic comparison of SBA with colorectal cancer and gastric carcinoma. The distinct genomic differences establish SBA as a molecularly unique intestinal cancer. In addition, genomic profiling can identify potentially targetable genomic alterations in the majority of SBA cases (91%), and the higher incidence of microsatellite instability and tumor mutational burden in SBA suggests a potential role for immunotherapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017. PMID: 28617917. doi:10.1001/jamaoncol.2017.1051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。